Detalhe da pesquisa
1.
Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
Clin Infect Dis
; 75(1): e525-e528, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35271729
2.
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study.
J Antimicrob Chemother
; 76(12): 3286-3295, 2021 11 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34450619
3.
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways.
Sci Rep
; 13(1): 6681, 2023 04 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37095160
4.
Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
Lancet Infect Dis
; 23(2): 183-195, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36272432
5.
Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
Nat Commun
; 13(1): 7284, 2022 11 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-36435798
6.
Single-Nucleotide Polymorphism to Associate Cancer Risk.
Methods Mol Biol
; 1381: 93-110, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26667457